The aim of this study was to compare more conclusively the efficacy and safety of
moxifloxacin, a new respiratory fluoroquinolone antibiotic, with β-lactam-based standard …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality
throughout the world. To investigate whether moxifloxacin monotherapy is associated with …

Based on recent guidelines for the management of community-acquired pneumonia, this
study was designed to evaluate the effectiveness of a new fluoroquinolone compared with …

An international multi-centre, randomized, prospective, double-blind study compared oral
moxifloxacin (200 mg or 400 mg once daily for 10 days) with oral clarithromycin (500 mg …

Background Community acquired pneumonia (CAP) is a major cause of morbidity,
hospitalization, and mortality worldwide. Management of CAP for many patients requires …

Background. The aim of this study was to show that sequential intravenous and oral
moxifloxacin monotherapy (400 mg once per day) is as efficacious and safe as a …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

The objective of this study was to assess the efficacy and safety of moxifloxacin versus
amoxicillin-clavulanate plus roxithromycin (comparator) in adult community-acquired …

OBJECTIVE: In this observational study, we compared the outcomes of moxifloxacin
monotherapy as compared to ß-lactam monotherapy as well as ß-lactam combination …

Community-acquired pneumonia (CAP) remains a common and serious illness with
approximately 2–4 million cases reported annually. Management of CAP is therapeutically …